NEOGEN CORP NEOG
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
3/9
Piotroski F — financial health
-0.23
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $894.7M | -$1.1B | $421.4M | — | $2.1B |
| 2024 | $924.2M | -$9.4M | $463.9M | — | $3.1B |
| 2023 | $822.4M | -$22.9M | $406.0M | — | $3.1B |
| 2022 | $527.2M | $48.3M | $243.0M | — | $887.4M |
| 2021 | $468.5M | $60.9M | $215.1M | — | $840.4M |
| 2020 | $418.2M | $59.5M | $196.3M | — | $725.2M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Moylan John Patrick | Chief Accounting Officer | 2026-06-03 | Tax withheld | 2,553 | $8.75 |
| Rocklin Amy M | Former Chief Legal Officer | 2026-05-18 | Option exercise | 35,183 | $9.29 |
| Rocklin Amy M | Former Chief Legal Officer | 2026-05-18 | Tax withheld | 10,241 | $9.29 |
| Moylan John Patrick | Chief Accounting Officer | 2026-05-04 | Tax withheld | 1,568 | $9.53 |
| Moylan John Patrick | Chief Accounting Officer | 2026-05-04 | Option exercise | 4,558 | $9.53 |
| Stacey Jennifer Evans | Chief Legal Officer | 2026-05-01 | Grant | 39,349 | $9.53 |
| Nassif Mikheal | CEO | 2026-02-17 | Buy | 23 | $10.94 |
| Nassif Mikheal | CEO | 2026-02-02 | Buy | 24 | $10.00 |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.23 (distress)
- Working capital / assets 0.117
- Retained earnings / assets -0.156
- EBIT / assets -0.308
- Equity / liabilities 1.509
Source: SEC EDGAR filings · CIK 0000711377 · as of 2025-05-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.